モリモト　サトシ   Morimoto Satoshi   森本　聡    所属   医学部 医学科（東京女子医科大学病院）    職種   准教授
論文種別	総説
言語種別	英語
査読の有無	査読あり
招待の有無	招待あり
表題	Critical appraisal and pooled analysis of telmisartan alone or in combination with hydrochlorothiazide for achieving blood pressure goals.
掲載誌名	正式名：Integrated blood pressure control 略　 称：Integr Blood Press Control ISSNコード：11787104/11787104
掲載区分	国外
巻・号・頁	3,pp.73-9
著者・共著者	Morimoto Satoshi†*, Takahashi Nobuyuki, Morita Tatsuyori, Someya Kazunori, Toyoda Nagaoki, Iwasaka Toshiji
担当区分	筆頭著者,責任著者
発行年月	2010
概要	Rigid control of blood pressure (BP) is essential to prevent cardiovascular disease. However, only about 40% of hypertensive patients undergoing pharmacological intervention with a single agent achieve their BP goals in contemporary clinical practice. Combined therapy using currently available agents is effective in maximizing treatment outcome, although it raises medical costs and decreases the drug compliance rate. To overcome such negative consequences, a combination tablet containing an angiotensin II receptor blocker (ARB) with a small dose of hydrochlorothiazide (HCTZ) is now available on the international market, including Japan. This article briefly describes the unique properties of telmisartan, a highly selective ARB for the angiotensin II type 1 receptor, including its long-acting characteristics and recent prospective multicenter randomized clinical trials, followed by a description of a newly-introduced combination tablet in Japan, which contains telmisartan and HCTZ. This article also reviews its safety and efficacy based on currently available evidence. Finally, evidence comparing telmisartan/HCTZ with other combination therapies is presented.
DOI	10.2147/ibpc.s9325
PMID	21949623